What we do Innovassynth Technologies (India) Ltd specializes in custom research, development, and manufacturing of specialty chemicals and nucleosides with a global export focus. |
Founded in 2,008 |
Market share Known for integrated manufacturing and CRDMO services, it holds a niche position in specialty chemicals and life sciences with over 90% export revenue. |
Problem solved Provides innovative chemical synthesis and manufacturing solutions to pharmaceutical and specialty chemical industries, enabling scalable, cost-effective production. |
Top clients or who we serve Serves global B2B customers primarily in the pharmaceutical and specialty chemicals sectors, focusing on US and European markets. |
Key management Dr. Hardik Joshipura (Managing Director) with strong leadership in R&D and operations. |
Our journey and innovations Evolved from an investment firm to a CRDMO with state-of-the-art facilities; recent merger for operational consolidation and growth. |
Where we operate India-based with export markets predominantly in the USA and Europe. |
Top products or what we offer Custom Research, Development and Manufacturing Operations (CRDMO) in Life Sciences & Nucleosides and Specialty Chemicals. |
Top brands Not specified; company offers proprietary and customer-specific chemical intermediates and nucleosides products. |
Raw materials needed Specialty chemical raw materials and intermediates required for synthesis and manufacturing processes. |
Raw materials supplier Details not specified; focus on backward integration to enhance supply competitiveness. |
Recurring vs cyclical contribution Revenue is project and order-based with recurring contracts in specialty product manufacturing. |
Our industry position Strong niche player in specialty chemicals and life sciences CRDMO with over 90% export-driven revenue. |
Financial highlights Q3 FY26 Revenue INR 22 Cr; YTD Revenue INR 52 Cr; EBITDA and PAT currently negative with strong order book INR 146 Cr. |
Geographical revenue split Approximately 70% USA, 26% Europe, and 4% Rest of World markets. |
Order book Order book stands at approximately INR 146 Cr across Life Sciences and Specialty Chemicals segments. |
Whats driving growth New product pipeline commercialization, export market demand, backward integration, and process improvements. |
Our future plans Focus on scaling commercial products, enhancing operational efficiency post-merger, and expanding global customer base. |
Our green promise Ecovadis Gold Rating for two consecutive years; initiating Science-Based Targets initiative in 2026. |
Our people and values Over 60 employees including 50+ scientists; emphasis on innovation, compliance, and ethical business practices. |
Key challenges ahead Short-term profitability, market volatility, and timely commercialization of products. |
Interesting facts Integrated complex with nine multipurpose manufacturing plants near Mumbai; recognized globally for quality standards. |
Risks and strategy Risks include profitability pressures and market shifts; strategies focus on R&D innovation and operational consolidation. |
